ISSN 1866-8836
Клеточная терапия и трансплантация

PC-02. Usage of vedolizumab in the treatment of GvHD in children: experience of the N. N. Blokhin National Medical Research Center of Oncology

Natalia A. Burlaka, Karina A. Sergeenko, Irina O. Kostareva, Teymur Z. Aliev, Konstantin V. Mitrakov, Tatiana I. Potemkina, Vasily P. Akimov, Nune V. Matinyan, Dmitry V. Rogozhin, Timur T. Valiev, Natalia A. Batmanova, Elena B. Machneva, Kirill I. Kirgizov, Svetlana R. Varfolomeeva

L. Durnov Research Institute of Pediatric Oncology and Hematology at the N. N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia


Contact: Natalya A. Burlaka, phone: +7 (916) 334-73-67, e-mail: Dreamfull2009@yandex.ru

doi 10.18620/ctt-1866-8836-2023-12-3-1-176

Summary

Therapy of refractory forms of graft-versus-host reaction (GvHD), especially intestinal GvHD, is still an unresolved problem. It is required to determine the place of vedolizumab (VD) in modern practice and its safety. Taking into account the experience of the drug, its selective effect, VD can potentially improve the results of the treatment with GvHD refractory to standard therapy. Purpose of our work was to present the experience of using vedolizumab in the treatment of GvHD in children after allogeneic HSCT at N. N. Blokhin National Medical Research Center of Oncology.

Materials and methods

The study included 9 patients. M:F ratio was 4:5, with following diagnoses: AML (n=3), ALL (n=3), LL (n=1), UMML (n=1), NB (n=1). HSCT types: unrelated 9/10 with PtCy (n=4), haplo-Cy (n=3), haplo with TCR a/b/CD19 depletion (n=2). aGvHD grade: stage 1-2 (n=4), stage 3-4 (n=5). Immunosuppressive therapy in addition to VD: steroid therapy, cyclosporine A, ruxolitinib, etanercept, rituximab, tacrolimus. Median occurrence of aGvHD: 45 days (30-120). Median number of VD injections: 3 times (2-4).

Results

All patients did not exhibit severe adverse events with vedolizumab. 7 out of 9 patients are alive. The median observation time is 7 months (4-10). The surviving patients are observed without signs of intestinal form of GvHD.

Conclusion

Vedolizumab showed efficacy in the treatment of refractory forms of GvHD in children treated at the N. N. Blokhin National Medical Research Center of Oncology. The development of significant adverse reactions was not recorded.

Keywords

Allogeneic hematopoietic stem cell transplantation, GvHD, vedolizumab, children.


Supplement 12-3
09/30/2023

Download PDF version

doi 10.18620/ctt-1866-8836-2023-12-3-1-176

Back to the list